Physician profile
Dina Began
NPI 1497862346
$14,399.60
in general payments reported to CMS, 2019-2025
36 companies · $3,986 in 2025
The $3,986 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $791 · 2021: $1,835 · 2022: $1,260 · 2023: $2,777 · 2024: $2,660 · 2025: $3,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,197 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,197.26 |
| Education | $224.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,293.28 | 2020-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $1,252.12 | 2019-2025 | Nemluvio, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,141.58 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Pfizer INC. | $1,065.43 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $957.01 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $931.71 | 2022-2024 | Vtama |
| Genzyme Corporation | $923.53 | 2021-2025 | |
| Medimetriks Pharmaceuticals, INC. | $900.00 | 2021 | |
| Leo Pharma INC. | $878.91 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $870.40 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $744.18 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $518.79 | 2019-2025 | Dupixent |
| Incyte Corporation | $438.79 | 2021-2025 | Opzelura, Opzelura |
| Amgen INC. | $438.36 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $341.59 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $332.72 | 2023-2025 | Sotyktu, Sprycel |
| Almirall LLC | $242.29 | 2021-2025 | Seysara, Klisyri |
| Journey Medical Corporation | $241.25 | 2019-2025 | |
| Ucb, INC. | $232.90 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $127.35 | 2023-2025 | |
| Epi Health, LLC | $80.89 | 2019-2022 | |
| Lilly USA, LLC | $80.52 | 2020-2021 | |
| Botanix Sb INC | $50.07 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $39.97 | 2019 | |
| Exact Sciences Corporation | $34.77 | 2025 | Cologuard Collection Kit |
| Sandoz INC. | $31.18 | 2020 | |
| Prugen, INC. Pharmaceuticals | $29.21 | 2019 | |
| Mission Pharmacal Company | $27.76 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $26.75 | 2020 | |
| Boston Scientific Corporation | $23.59 | 2021 | |
| Mimedx Group, INC. | $19.60 | 2024 | |
| Fidia Pharma USA INC. | $18.74 | 2024 | |
| Dermira, INC. | $17.14 | 2020 | |
| Organon LLC | $16.53 | 2025 | Vtama |
| Cipher Pharmaceuticals US LLC | $15.90 | 2025 | Spinosad, Natroba |
| Paratek Pharmaceuticals, INC. | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Began listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.